Literature DB >> 29949454

Barriers to accessing treatment for pregnant women with opioid use disorder in Appalachian states.

Stephen W Patrick1,2,3,4, Melinda B Buntin4, Peter R Martin5,6, Theresa A Scott1,2, William Dupont7, Michael Richards4, William O Cooper1,4.   

Abstract

Background and aims: Opioid agonist therapies (OATs) are highly effective treatments for opioid use disorders (OUDs), especially for pregnant women; thus, improving access to OAT is an urgent public policy goal. Our objective was to determine if insurance and pregnancy status were barriers to obtaining access to OAT in 4 Appalachian states disproportionately impacted by the opioid epidemic.
Methods: Between April and May 2017, we conducted phone surveys of OAT providers, opioid treatment programs (OTPs), and outpatient buprenorphine providers, in Kentucky, North Carolina, Tennessee, and West Virginia. Survey response rates were 59%. Logistic models for dichotomous outcomes (e.g., patient acceptance) and negative binomial models were created for count variables (e.g., wait time), overall and for pregnant women.
Results: The majority of OAT providers were accepting new patients; however, providers were less likely to treat pregnant women (91% vs. 75%; p < .01). OTPs were more likely to accept new patients than waivered buprenorphine providers (97% vs. 83%; p = .01); rates of accepting pregnant patients were lower in both (91% and 53%; p < .01). OTPs and buprenorphine providers accepted cash payments for services at high rates (OTP: 100%; buprenorphine: 89.4%; p < .01); Medicaid and private insurance were accepted at lower rates. In adjusted models, providers were less likely to accept pregnant women if they took any insurance (adjusted odds ratio [aOR] = 0.15, 95% confidence interval [CI]: 0.03-0.68) or were a buprenorphine provider (aOR = 0.09, 95% CI: 0.02-0.37). Conclusions: We found that OAT providers frequently did not accept any insurance and frequently did not treat pregnant women in an area of the country disproportionately affected by the opioid epidemic. Policymakers could prioritize improvements in provider training (e.g., training of obstetricians to become buprenorphine prescribers) as a means to enhance access to pregnant women or enhancing reimbursement rates as a means of improving insurance acceptance for OAT.

Entities:  

Keywords:  Appalachia; Opioid agonist therapies (OAT); buprenorphine; insurance; opioid treatment programs (OTPs); opioid use disorder (OUD); pregnant women

Mesh:

Substances:

Year:  2018        PMID: 29949454      PMCID: PMC9069995          DOI: 10.1080/08897077.2018.1488336

Source DB:  PubMed          Journal:  Subst Abus        ISSN: 0889-7077            Impact factor:   3.984


  6 in total

Review 1.  Opioid Use Disorder in Pregnancy: Health Policy and Practice in the Midst of an Epidemic.

Authors:  Elizabeth E Krans; Stephen W Patrick
Journal:  Obstet Gynecol       Date:  2016-07       Impact factor: 7.661

2.  ACOG Committee Opinion No. 524: Opioid abuse, dependence, and addiction in pregnancy.

Authors: 
Journal:  Obstet Gynecol       Date:  2012-05       Impact factor: 7.661

3.  Increasing incidence of the neonatal abstinence syndrome in U.S. neonatal ICUs.

Authors:  Veeral N Tolia; Stephen W Patrick; Monica M Bennett; Karna Murthy; John Sousa; P Brian Smith; Reese H Clark; Alan R Spitzer
Journal:  N Engl J Med       Date:  2015-04-26       Impact factor: 91.245

4.  Incidence of Neonatal Abstinence Syndrome - 28 States, 1999-2013.

Authors:  Jean Y Ko; Stephen W Patrick; Van T Tong; Roshni Patel; Jennifer N Lind; Wanda D Barfield
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2016-08-12       Impact factor: 17.586

5.  Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012.

Authors:  S W Patrick; M M Davis; C U Lehmann; C U Lehman; W O Cooper
Journal:  J Perinatol       Date:  2015-04-30       Impact factor: 2.521

6.  Prescription Opioid Use, Misuse, and Use Disorders in U.S. Adults: 2015 National Survey on Drug Use and Health.

Authors:  Beth Han; Wilson M Compton; Carlos Blanco; Elizabeth Crane; Jinhee Lee; Christopher M Jones
Journal:  Ann Intern Med       Date:  2017-08-01       Impact factor: 25.391

  6 in total
  27 in total

1.  Medication-Assisted Treatment Use Among Pregnant Women With Opioid Use Disorder.

Authors:  Elizabeth E Krans; Joo Yeon Kim; Alton Everette James; David Kelley; Marian P Jarlenski
Journal:  Obstet Gynecol       Date:  2019-05       Impact factor: 7.661

2.  The Affordable Care Act In The Heart Of The Opioid Crisis: Evidence From West Virginia.

Authors:  Brendan Saloner; Rachel Landis; Bradley D Stein; Colleen L Barry
Journal:  Health Aff (Millwood)       Date:  2019-04       Impact factor: 6.301

3.  Early lessons from maternal mortality review committees on drug-related deaths-time for obstetrical providers to take the lead in addressing addiction.

Authors:  Marcela C Smid; Charles W Schauberger; Mishka Terplan; Tricia E Wright
Journal:  Am J Obstet Gynecol MFM       Date:  2020-07-15

4.  Access to Office-Based Buprenorphine Treatment in Areas With High Rates of Opioid-Related Mortality: An Audit Study.

Authors:  Tamara Beetham; Brendan Saloner; Sarah E Wakeman; Marema Gaye; Michael L Barnett
Journal:  Ann Intern Med       Date:  2019-06-04       Impact factor: 25.391

5.  Opioid Use Disorder Treatment Facilities With Programs for Special Populations.

Authors:  Scott E Hadland; Victoria A Jent; Rachel H Alinsky; Brandon D L Marshall; Pia M Mauro; Magdalena Cerdá
Journal:  Am J Prev Med       Date:  2020-05-21       Impact factor: 5.043

6.  Medical specialty of buprenorphine prescribers for pregnant women with opioid use disorder.

Authors:  Mara A G Hollander; Marian P Jarlenski; Julie M Donohue; Evan S Cole; David Kelley; Elizabeth E Krans
Journal:  Am J Obstet Gynecol       Date:  2019-01-28       Impact factor: 8.661

7.  Implementing a Learning Collaborative Framework for States Working to Improve Outcomes for Vulnerable Populations: The Opioid Use Disorder, Maternal Outcomes, and Neonatal Abstinence Syndrome Initiative Learning Community.

Authors:  Charlan D Kroelinger; Donna Addison; Mirelys Rodriguez; Marion E Rice; Meghan T Frey; Hadley R Hickner; Mary Kate Weber; Trish Mueller; Alisa Velonis; Keriann Uesugi; Lisa Romero; Sanaa Akbarali; Natalie Foster; Jean Y Ko; Ellen Pliska; Christine Mackie; Shanna Cox; S Nicole Fehrenbach; Wanda D Barfield
Journal:  J Womens Health (Larchmt)       Date:  2020-03-13       Impact factor: 2.681

8.  Substance use disorder treatment services for pregnant and postpartum women in residential and outpatient settings.

Authors:  Angélica Meinhofer; Jesse M Hinde; Mir M Ali
Journal:  J Subst Abuse Treat       Date:  2019-12-06

9.  Treatment of Substance Use Disorders Among Women of Reproductive Age by Depression and Anxiety Disorder Status, 2008-2014.

Authors:  Jiani Zhou; Jean Y Ko; Sarah C Haight; Van T Tong
Journal:  J Womens Health (Larchmt)       Date:  2019-07-12       Impact factor: 2.681

10.  Antenatal Admissions Among Women with Opioid-Affected and Non-Opioid-Affected Deliveries.

Authors:  Laura J Faherty; Ashley M Kranz; Joshua Russell-Fritch; Teague Ruder; Stephen W Patrick; Bradley D Stein
Journal:  Matern Child Health J       Date:  2020-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.